Cite
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
MLA
Benfield, Thomas, et al. “Safety, Tolerability, and Immunogenicity of V114 Pneumococcal Vaccine Compared with PCV13 in a 2+1 Regimen in Healthy Infants: A Phase III Study (PNEU-PED-EU-2).” Vaccine, vol. 41, no. 15, Apr. 2023, pp. 2456–65. EBSCOhost, https://doi.org/10.1016/j.vaccine.2023.02.041.
APA
Benfield, T., Rämet, M., Valentini, P., Seppä, I., Dagan, R., Richmond, P., Mercer, S., Churchill, C., Lupinacci, R., McFetridge, R., Park, J., Wittke, F., Banniettis, N., Musey, L., Bickham, K., & Kaminski, J. (2023). Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Vaccine, 41(15), 2456–2465. https://doi.org/10.1016/j.vaccine.2023.02.041
Chicago
Benfield, Thomas, Mika Rämet, Piero Valentini, Ilkka Seppä, Ron Dagan, Peter Richmond, Swati Mercer, et al. 2023. “Safety, Tolerability, and Immunogenicity of V114 Pneumococcal Vaccine Compared with PCV13 in a 2+1 Regimen in Healthy Infants: A Phase III Study (PNEU-PED-EU-2).” Vaccine 41 (15): 2456–65. doi:10.1016/j.vaccine.2023.02.041.